EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

A Systematic Review and Meta-Analysis of Supramarginal Resection versus Gross Total Resection in Glioblastoma: Can We Enhance Progression-Free Survival Time and Preserve Postoperative Safety?

Johannes Wach iD, Martin Vychopen, Andreas Kühnapfel iD, Clemens Seidel, Erdem Güresir iD

Cancers · 15.03.2023 · 15 (6) · 1772

DOI: 10.3390/cancers15061772 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 15.03.2023. Verfasst von Johannes Wach und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University Hospital Leipzig, 04103 Leipzig, Germany. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To date, gross total resection (GTR) of the contrast-enhancing area of glioblastoma (GB) is the benchmark treatment regarding surgical therapy. However, GB infiltrates beyond those margins, and most tumors recur in close proximity to the initial resection margin. It is unclear whether a supramarginal resection (SMR) enhances progression-free survival (PFS) time without increasing the incidence of postoperative surgical complications. The aim of the present meta-analysis was to investigate SMR with regard to PFS and postoperative surgical complications. We searched for eligible studies comparing SMR techniques with conventional GTR in PubMed, Cochrane Library, Web of Science, and Medline databases. From 3158 initially identified records, 11 articles met the criteria and were included in our meta-analysis. Our results illustrate significantly prolonged PFS time in SMR compared with GTR (HR: 11.16; 95% CI: 3.07–40.52, p = 0.0002). The median PFS of the SMR arm was 8.44 months (95% CI: 5.18–11.70, p < 0.00001) longer than the GTR arm. The rate of postoperative surgical complications (meningitis, intracranial hemorrhage, and CSF leaks) did not differ between the SMR group and the GTR group. SMR resulted in longer median progression-free survival without a negative postoperative surgical risk profile. Multicentric prospective randomized trials with a standardized definition of SMR and analysis of neurologic functioning and health-related quality of life are justified and needed to improve the level of evidence.

Schlagwörter

Stichwörter der Autor:innen

extent of resectionglioblastomameta-analysisprogression-free survivalsupramarginal resection

Autor:innen und Institutionen

  • Department of Neurosurgery, University Hospital Leipzig, 04103 Leipzig, Germany.
  • Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, 04107 Leipzig, Germany.
  • Department of Radiation Oncology, University Hospital Leipzig, 04103 Leipzig, Germany.

ORCID-Profile: Johannes Wach, Andreas Kühnapfel, Erdem Güresir

Zitieren

APA

Wach, J., Vychopen, M., Kühnapfel, A., Seidel, C., & Güresir, E. (2023). A Systematic Review and Meta-Analysis of Supramarginal Resection versus Gross Total Resection in Glioblastoma: Can We Enhance Progression-Free Survival Time and Preserve Postoperative Safety?. Cancers, 15(6), 1772. https://doi.org/10.3390/cancers15061772

Vancouver

Wach J, Vychopen M, Kühnapfel A, Seidel C, Güresir E. A Systematic Review and Meta-Analysis of Supramarginal Resection versus Gross Total Resection in Glioblastoma: Can We Enhance Progression-Free Survival Time and Preserve Postoperative Safety?. Cancers. 2023;15(6):1772. doi:10.3390/cancers15061772

BibTeX
@article{Wach2023,
  author = {Wach, Johannes and Vychopen, Martin and Kühnapfel, Andreas and Seidel, Clemens and Güresir, Erdem},
  title = {A Systematic Review and Meta-Analysis of Supramarginal Resection versus Gross Total Resection in Glioblastoma: Can We Enhance Progression-Free Survival Time and Preserve Postoperative Safety?},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {6},
  pages = {1772},
  doi = {10.3390/cancers15061772}
}
Kostenlos starten →